345 related articles for article (PubMed ID: 12200805)
1. Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis.
Hainer JW; Sherrard DJ; Swan SK; Barrett JS; Assaid CA; Fossler MJ; Cox DS; Williams RM; Pittenger AL; Stephenson CA; Hua TA
Am J Kidney Dis; 2002 Sep; 40(3):531-8. PubMed ID: 12200805
[TBL] [Abstract][Full Text] [Related]
2. Elderly patients treated with tinzaparin (Innohep) administered once daily (175 anti-Xa IU/kg): anti-Xa and anti-IIa activities over 10 days.
Siguret V; Pautas E; Février M; Wipff C; Durand-Gasselin B; Laurent M; Andreux JP; d'Urso M; Gaussem P
Thromb Haemost; 2000 Nov; 84(5):800-4. PubMed ID: 11127859
[TBL] [Abstract][Full Text] [Related]
3. Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center.
Lord H; Jean N; Dumont M; Kassis J; Leblanc M
Am J Nephrol; 2002; 22(1):58-66. PubMed ID: 11919404
[TBL] [Abstract][Full Text] [Related]
4. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
[TBL] [Abstract][Full Text] [Related]
5. Tinzaparin versus dalteparin for periprocedure prophylaxis of thromboembolic events in hemodialysis patients: a randomized trial.
Rodger MA; Ramsay T; MacKinnon M; Westphal M; Wells PS; McCormick B; Knoll G
Am J Kidney Dis; 2012 Sep; 60(3):427-34. PubMed ID: 22480794
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two low-molecular weight heparins (LMWHs), tinzaparin and bemiparin, during hemodialysis.
Christidou FN; Frangia TK; Bamichas GI; Gionanlis LC; Natse TA; Georgoulis IE; Sombolos KI
Int J Clin Pharmacol Ther; 2005 Jul; 43(7):335-8. PubMed ID: 16035376
[TBL] [Abstract][Full Text] [Related]
7. Anticoagulant pharmacodynamics of tinzaparin following 175 iu/kg subcutaneous administration to healthy volunteers.
Barrett JS; Hainer JW; Kornhauser DM; Gaskill JL; Hua TA; Sprogel P; Johansen K; van Lier JJ; Knebel W; Pieniaszek HJ
Thromb Res; 2001 Feb; 101(4):243-54. PubMed ID: 11248285
[TBL] [Abstract][Full Text] [Related]
8. Tinzaparin sodium: a review of its pharmacology and clinical use in the prophylaxis and treatment of thromboembolic disease.
Cheer SM; Dunn CJ; Foster R
Drugs; 2004; 64(13):1479-502. PubMed ID: 15212562
[TBL] [Abstract][Full Text] [Related]
9. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.
Hirsh J; Raschke R
Chest; 2004 Sep; 126(3 Suppl):188S-203S. PubMed ID: 15383472
[TBL] [Abstract][Full Text] [Related]
10. Anti-Xa activity supports using a simple dosing algorithm for tinzaparin for anticoagulation in hemodialysis.
Kirwan CJ; Baig ZF; Platton S; MacCullum PK; Ashman N
Nephron Clin Pract; 2013; 123(1-2):7-12. PubMed ID: 23751953
[TBL] [Abstract][Full Text] [Related]
11. Repeated Oral or Subcutaneous LMWH Has similar Antithrombotic Activity in a Rat Venous Thrombosis Model: Antithrombotic Activity Correlates With Heparin on Endothelium When Orally Administered.
Hiebert LM
J Cardiovasc Pharmacol Ther; 2017 May; 22(3):264-272. PubMed ID: 27653610
[TBL] [Abstract][Full Text] [Related]
12. Empirically Reduced Dosages of Tinzaparin in Patients with Moderate-to-Severe Renal Insufficiency Lead to Inadequate Anti-Xa Levels.
Olie RH; Meertens NEL; Henskens YMC; Ten Cate H
Nephron; 2017; 137(2):113-123. PubMed ID: 28662505
[TBL] [Abstract][Full Text] [Related]
13. Weight-adjusted dosing of tinzaparin in pregnancy.
Gibson PS; Newell K; Sam DX; Mansoor A; Jiang X; Tang S; Ross S
Thromb Res; 2013 Feb; 131(2):e71-5. PubMed ID: 23245654
[TBL] [Abstract][Full Text] [Related]
14. Pharmacodynamics of intravenous and subcutaneous tinzaparin and heparin in healthy volunteers.
Fossler MJ; Barrett JS; Hainer JW; Riddle JG; Ostergaard P; van der Elst E; Sprogel P
Am J Health Syst Pharm; 2001 Sep; 58(17):1614-21. PubMed ID: 11556655
[TBL] [Abstract][Full Text] [Related]
15. Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study.
Hainer JW; Barrett JS; Assaid CA; Fossler MJ; Cox DS; Leathers T; Leese PT
Thromb Haemost; 2002 May; 87(5):817-23. PubMed ID: 12038783
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of coagulation and anti-Xa factor when using a heparin-coated AN69ST® dialyser.
Sánchez-Canel JJ; Pons-Prades R; Salvetti ML; Seores A; Vázquez M; Pérez-Alba A; Tamarit E; Calvo-Gordo C; Villatoro J
Nefrologia; 2012; 32(5):605-12. PubMed ID: 23013946
[TBL] [Abstract][Full Text] [Related]
17. Thromboprophylaxis following caesarean section--a comparison of the antithrombotic properties of three low molecular weight heparins--dalteparin, enoxaparin and tinzaparin.
Ellison J; Thomson AJ; Conkie JA; McCall F; Walker D; Greer A
Thromb Haemost; 2001 Dec; 86(6):1374-8. PubMed ID: 11776302
[TBL] [Abstract][Full Text] [Related]
18. Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study.
Mahé I; Aghassarian M; Drouet L; Bal Dit-Sollier C; Lacut K; Heilmann JJ; Mottier D; Bergmann JF
Thromb Haemost; 2007 Apr; 97(4):581-6. PubMed ID: 17393021
[TBL] [Abstract][Full Text] [Related]
19. [Monitoring of tinzaparin in a ten day treatment dose in elderly patients].
Pautas E; Siguret V; d'Urso M; Laurent M; Gaussem P; Février M; Durand-Gasselin B
Rev Med Interne; 2001 Feb; 22(2):120-6. PubMed ID: 11234669
[TBL] [Abstract][Full Text] [Related]
20. Dose titration study of tinzaparin, a low molecular weight heparin, in patients on chronic hemodialysis.
Egfjord M; Rosenlund L; Hedegaard B; Buchardt HL; Stengel C; Gardar P; Andersen L; Andersen L
Artif Organs; 1998 Aug; 22(8):633-7. PubMed ID: 9702313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
